Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a computer match experts in finding lingering leukemia?

NCT ID NCT07269067

First seen Jan 10, 2026 · Last updated Jun 21, 2026 · Updated 30 times

Summary

This study looks at two methods for detecting minimal residual disease (MRD) in acute myeloid leukemia (AML) patients after chemotherapy. One method relies on expert manual analysis, while the other uses a computer algorithm called FlowSOM. Researchers will compare results from 60 patients to see if the automated approach is as accurate as the manual one.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could make MRD detection faster and more consistent, potentially improving leukemia monitoring.

What could go wrong

This is a small, retrospective study (60 patients) from one hospital. The automated method may not match manual accuracy in all cases.

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.